Original ArticleCycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells
-
Add time:09/10/2019 Source:sciencedirect.com
BackgroundCycloastragenol (CAG), a triterpene aglycone is commonly prescribed for treating hypertension, cardiovascular disease, diabetic nephropathy, viral hepatitis, and various inflammatory-linked diseases.
We also recommend Trading Suppliers and Manufacturers of PACLITAXEL SIDE CHAIN NO 1 (cas 133066-61-2). Pls Click Website Link as below: cas 133066-61-2 suppliers
Prev:Synthesis, isolation, stereostructure and cytotoxicity of paclitaxel analogs from cephalomannine
Next:The effect of surfactants modification on nanocrystalline cellulose for paclitaxel loading and release study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The effect of surfactants modification on nanocrystalline cellulose for paclitaxel loading and release study09/24/2019
- Synthesis, isolation, stereostructure and cytotoxicity of paclitaxel analogs from cephalomannine09/09/2019
- Historical PerspectiveBasic principles of drug delivery systems – the case of paclitaxel09/08/2019
- Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro09/07/2019
- Topical PerspectivesToward an ab initio potential energy surface for paclitaxel: A C-13 isoserine side chain conformational study09/06/2019
- Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates09/05/2019
- Design, synthesis and biological evaluation of paclitaxel-mimics possessing only the oxetane D-ring and side chain structures09/04/2019
- A convenient one-pot approach to Paclitaxel (Taxol) side chain via 1,3-dipolar cycloaddition of carbonyl ylides and N-benzoylbenzyl imines09/03/2019
-
Health and Chemical more >